Prosperity Wealth Management Inc. Boosts Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Prosperity Wealth Management Inc. raised its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 2.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,266 shares of the biotechnology company’s stock after purchasing an additional 55 shares during the period. Prosperity Wealth Management Inc.’s holdings in Axon Enterprise were worth $585,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. increased its holdings in Axon Enterprise by 11.7% in the 1st quarter. BlackRock Inc. now owns 8,329,479 shares of the biotechnology company’s stock worth $1,872,883,000 after acquiring an additional 870,481 shares in the last quarter. Capital International Investors increased its stake in shares of Axon Enterprise by 605.2% in the first quarter. Capital International Investors now owns 2,660,634 shares of the biotechnology company’s stock worth $366,449,000 after purchasing an additional 2,283,343 shares in the last quarter. Sands Capital Management LLC raised its position in shares of Axon Enterprise by 31.1% during the 3rd quarter. Sands Capital Management LLC now owns 2,612,305 shares of the biotechnology company’s stock valued at $519,823,000 after purchasing an additional 619,179 shares during the period. State Street Corp lifted its stake in shares of Axon Enterprise by 12.6% during the 1st quarter. State Street Corp now owns 2,377,095 shares of the biotechnology company’s stock valued at $534,484,000 after buying an additional 266,465 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Axon Enterprise by 3.3% in the 3rd quarter. Wellington Management Group LLP now owns 1,956,022 shares of the biotechnology company’s stock worth $389,229,000 after buying an additional 62,324 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on AXON. Argus began coverage on Axon Enterprise in a report on Wednesday, March 13th. They set a “buy” rating and a $380.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a research note on Thursday, April 11th. Barclays upped their price objective on Axon Enterprise from $296.00 to $308.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Robert W. Baird boosted their price target on shares of Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, February 22nd. Finally, Morgan Stanley boosted their price objective on Axon Enterprise from $250.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and a consensus price target of $312.64.

Axon Enterprise Trading Down 0.7 %

Shares of Axon Enterprise stock traded down $2.22 on Wednesday, hitting $298.09. 132,007 shares of the company traded hands, compared to its average volume of 460,866. The company has a current ratio of 3.00, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42. The company has a market cap of $22.49 billion, a PE ratio of 130.57 and a beta of 0.93. The stock’s 50 day moving average price is $299.16 and its 200-day moving average price is $256.71. Axon Enterprise, Inc. has a 52 week low of $175.37 and a 52 week high of $329.87.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.29. The business had revenue of $432.14 million for the quarter, compared to the consensus estimate of $418.97 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. Equities research analysts predict that Axon Enterprise, Inc. will post 2.43 EPS for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.